VCP
BLFS icon

Verus Capital Partners’s BioLife Solutions BLFS Stock Holding History

Verus Capital Partners’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,000
Closed -$32K – 1478
2019
Q4 		$32K Buy
+2,000
New +$32.5K 0.01% 737

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SPA
Sentinel Pension Advisors Wakefield, Massachusetts $676M AUM 15.31% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
TC
Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return

Verus Capital Partners's BLFS Position: Q1 2020 in Review

Verus Capital Partners sold out of BioLife Solutions (BLFS) in Q1 2020, closing a stake of 2,000 shares — an estimated $32K sold.

Verus Capital Partners first reported a position in BLFS in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 75 funds tracked by Wall St. Rank hold BLFS as of Q1 2020.

  • Verus Capital Partners reported no remaining BioLife Solutions position as of Q1 2020 after selling out during the quarter.
  • Verus Capital Partners sold 2,000 BioLife Solutions shares in Q1 2020, an estimated $32K.
  • Verus Capital Partners first reported a position in BioLife Solutions in Q4 2019 and held it in 1 quarter.
  • Verus Capital Partners's BioLife Solutions position peaked at $32K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.